MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics, Inc. (KYTX)

|||

Balance Sheets Overview

Current Ratio
905.81%
Quick Ratio
905.81%
Cash Ratio
139.49%
Debt to Asset Ratio
24.69%
Unit: Thousand (K) dollars
Assets Breakdown
    • Available-for-sale marketable se...
    • Cash and cash equivalents
    • Operating lease right-of-use ass...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Term loan
    • Others
Balance Sheets
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
31,806
124,093
34,164
53,440
Available-for-sale marketable securities
167,621
155,160
136,974
158,237
Prepaid expenses and other current assets
7,115
3,700
3,787
2,650
Total current assets
206,542
282,953
174,925
214,327
Restricted cash
551
551
551
551
Property and equipment, net
1,326
1,546
1,793
2,162
Operating lease right-of-use assets
7,848
3,568
4,317
5,049
Finance lease right-of-use assets
112
305
212
366
Other non-current assets
3,444
4,903
5,358
4,053
Total assets
219,823
293,826
187,156
226,508
Accounts payable
2,933
5,306
3,016
9,917
Accrued compensation
5,481
9,990
6,960
4,971
Accrued license expense - related party
3,750
3,750
6,250
6,250
Other accrued expenses and current liabilities
9,112
13,472
13,960
15,075
Operating lease liabilities, short-term portion
1,400
3,662
3,495
3,284
Finance lease liabilities
126
307
190
292
Total current liabilities
22,802
36,487
33,871
39,789
Operating lease liabilities, net of short-term portion
6,589
320
1,331
2,316
Finance lease liabilities, net of short-term portion
-
0
8
26
Term loan
24,883
24,743
-
-
Total liabilities
54,274
61,550
35,210
42,131
Common stock, 0.00001 par value 490,000,000 shares authorized as of june 30, 2026 and december 31, 2025 61,570,247 and 60,389,893 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
1
1
-
-
Additional paid-in capital
668,564
657,005
538,940
534,633
Accumulated other comprehensive (loss) income
-142
97
29
-20
Accumulated deficit
-502,874
-424,827
-387,023
-350,236
Total stockholders' equity
165,549
232,276
151,946
184,377
Total liabilities and stockholders' equity
219,823
293,826
187,156
226,508
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Available-for-sale marketablesecurities$167,621K (5.93%↑ Y/Y)Cash and cashequivalents$31,806K (-40.48%↓ Y/Y)Prepaid expenses andother current assets$7,115K (168.49%↑ Y/Y)Total current assets$206,542K (-3.63%↓ Y/Y)Operating leaseright-of-use assets$7,848K (55.44%↑ Y/Y)Other non-currentassets$3,444K (-15.03%↓ Y/Y)Property and equipment,net$1,326K (-38.67%↓ Y/Y)Restricted cash$551K (0.00%↑ Y/Y)Finance leaseright-of-use assets$112K (-69.40%↓ Y/Y)Total assets$219,823K (-2.95%↓ Y/Y)Total liabilities andstockholders' equity$219,823K (-2.95%↓ Y/Y)Total stockholders'equity$165,549K (-10.21%↓ Y/Y)Total liabilities$54,274K (28.82%↑ Y/Y)Accumulated deficit-$502,874K (-43.58%↓ Y/Y)Accumulated othercomprehensive (loss) income-$142K (-610.00%↓ Y/Y)Additional paid-in capital$668,564K (25.05%↑ Y/Y)Term loan$24,883K Total currentliabilities$22,802K (-42.69%↓ Y/Y)Operating leaseliabilities, net of...$6,589K (184.50%↑ Y/Y)Common stock, 0.00001par value...$1K Other accruedexpenses and current...$9,112K (-39.56%↓ Y/Y)Accrued compensation$5,481K (10.26%↑ Y/Y)Accrued license expense- related party$3,750K (-40.00%↓ Y/Y)Accounts payable$2,933K (-70.42%↓ Y/Y)Operating leaseliabilities, short-term...$1,400K (-57.37%↓ Y/Y)Finance leaseliabilities$126K (-56.85%↓ Y/Y)